Lucid Diagnostics (LUCD) Stock Analysis & Winston Score
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company wa
Winston Score: 18/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (1/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Weak (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
